A patient with seizures on levetiracetam (Keppra) has a critically low white blood cell count (WBC 2.4 ×10⁹/L); how should I manage this?

Management of Critical Leukopenia (WBC 2.4) in a Patient on Levetiracetam

Continue levetiracetam and monitor the patient closely, as this degree of leukopenia is a known but typically benign effect of the medication that rarely requires discontinuation.

Understanding Levetiracetam-Associated Leukopenia

Levetiracetam causes minor but statistically significant decreases in white blood cell counts compared to placebo, with 3.2% of treated patients experiencing at least one possibly significant decreased WBC (≤2.8 × 10⁹/L) versus 1.8% of placebo patients 1. Your patient's WBC of 2.4 × 10⁹/L falls into this category.

Critically, the FDA label explicitly states that "of the treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment" and "no patient was discontinued secondary to low neutrophil counts" 1. This is fundamentally different from drugs like clozapine or carbamazepine, where severe neutropenia mandates immediate discontinuation.

Immediate Assessment Steps

Check the Absolute Neutrophil Count (ANC)

• Obtain a complete blood count with differential immediately to calculate the ANC 2
• The critical threshold is ANC < 1.0 × 10⁹/L, not just the total WBC 3
• If ANC ≥ 1.0 × 10⁹/L, the patient is at low risk for infection despite the low total WBC 3

Evaluate for Alternative Causes

• Review all concurrent medications that could contribute to leukopenia (other anticonvulsants, antibiotics, immunosuppressants) 2
• Assess for signs of infection (fever, localizing symptoms, vital sign instability) that would indicate neutropenia-related complications 2
• Consider underlying hematologic disorders if the patient has other cytopenias or abnormal cell morphology 2

Management Algorithm Based on ANC

If ANC ≥ 1.5 × 10⁹/L

• Continue levetiracetam at current dose 1
• Repeat CBC with differential in 1 week, then every 2 weeks until stable 3
• Educate the patient to report fever, sore throat, or signs of infection immediately 1

If ANC 1.0–1.5 × 10⁹/L

• Continue levetiracetam but increase monitoring frequency 3
• Repeat CBC with differential every 3–7 days until the trend is clear 3
• Avoid other myelosuppressive agents if possible 3
• Consider infectious disease consultation if fever develops 2

If ANC < 1.0 × 10⁹/L

• Hold levetiracetam temporarily and monitor daily CBC with differential 3
• Evaluate for infection aggressively with blood cultures, urinalysis, and chest imaging if clinically indicated 2
• Provide empiric broad-spectrum antibiotics if fever or signs of infection develop 2
• Resume levetiracetam at the same dose once ANC recovers to ≥ 1.5 × 10⁹/L 3
• If ANC remains < 1.0 × 10⁹/L for > 2 weeks despite holding levetiracetam, consider bone marrow aspiration to rule out unrelated hematologic pathology 3

Why Not Switch Anticonvulsants?

Levetiracetam-associated leukopenia is typically transient and self-limited, with most patients' counts rising toward baseline with continued treatment 1. Switching to alternative anticonvulsants carries significant risks:

• Phenytoin/fosphenytoin can cause more severe hematologic toxicity and requires cardiac monitoring 3, 4
• Valproate causes similar or greater decreases in WBC (mean decrease of 0.4 × 10⁹/L in pediatric studies) and carries additional risks of hepatotoxicity and teratogenicity 5, 6
• Carbamazepine is associated with more profound immunosuppression, including reduced immunoglobulin levels and increased infection risk 7
• Switching anticonvulsants introduces a period of subtherapeutic seizure control and potential breakthrough seizures 3, 4

Critical Pitfalls to Avoid

Do Not Confuse This with Clozapine-Type Agranulocytosis

• Clozapine requires immediate discontinuation if WBC drops below 3.0 × 10⁹/L or ANC below 1.5 × 10⁹/L 3
• Levetiracetam does not cause agranulocytosis and has a fundamentally different safety profile 1

Do Not Panic and Discontinue Unnecessarily

• The FDA label documents that no patients were discontinued from controlled trials for low WBC or neutrophil counts 1
• Premature discontinuation exposes the patient to seizure recurrence risk without clear benefit 3, 4

Do Not Ignore Concurrent Medications

• Valproate co-administration results in a significant decrease in total WBC (mean decrease from 6.96 to 6.13 × 10⁹/L) and neutrophils 5
• If the patient is on combination therapy, consider whether the other agent is the primary culprit 5, 7

Long-Term Monitoring Strategy

• Weekly CBC with differential for the first month, then every 2 weeks for 2 months, then monthly for 3 months 3
• Document the trend rather than reacting to a single value 1
• Most patients' counts stabilize within 3–6 months of continued therapy 1
• If counts remain stable and the patient is asymptomatic, monitoring can be reduced to every 3 months after the initial 6-month period 3

When to Consider Switching Anticonvulsants

• Persistent ANC < 1.0 × 10⁹/L despite holding levetiracetam for > 2 weeks 3
• Recurrent infections requiring hospitalization or IV antibiotics 2
• Progressive decline in WBC over multiple measurements despite dose reduction 2
• Patient or family preference after thorough discussion of risks and benefits 1

If switching is necessary, valproate or lamotrigine are reasonable alternatives, though both carry their own hematologic and immunologic risks 5, 7, 6. Avoid carbamazepine due to its association with reduced immunoglobulin levels and increased infection susceptibility 7.